Although ICI monotherapy failed to establish overall survival (OS) benefits in HCC,3 the IMbrave150 trial demonstrated that frontline use of the ICI atezolizumab in combination with bevacizumab (an anti‐vascular endothelial growth factor [VEGF]‐targeted therapy) conferred superior OS to the previous standard of care (sorafenib).4 This evidence concerns the gene VEGFA and hepatocellular carcinoma.